Loading...
Publication
Doença articular degenerativa em pacientes felinos- estudo prospetivo sobre o uso do INN-frunevetmab
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 834.77 KB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
Patologias articulares, nomeadamente a doença articular degenerativa, são cada vez
mais prevalentes e reconhecidas em contexto clínico e tão importante quanto o diagnóstico é o
seu tratamento. Neste contexto surgiu o INN-frunevetmab, um anticorpo monoclonal que atua
especificamente no fator de crescimento neural, impossibilitando que este se ligue a outros
recetores envolvidos na transmissão de sinais de dor e inflamação.
O presente estudo teve como objetivo avaliar a resposta ao uso terapêutico do INNfrunevetmab, no tratamento da dor crónica causada pela doença articular degenerativa em
gatos. Este foi realizado no Grupo Hospital do Gato em 50 gatos com diagnóstico de doença
articular degenerativa. Após o diagnóstico foi administrado INN-frunevetmab, por via subcutânea,
uma vez a cada 28 dias, na dose recomendada de 1-2,8 mg/kg. O nível de dor nos animais foi
determinado em dois momentos, antes (PA) e três meses após (PD) a administração do INNfrunevetmab, através de um questionário com 12 perguntas. Cada resposta assinalada pelo tutor
faria corresponder 1 ponto de dor. Os dados foram recolhidos e procedeu-se ao somatório das
pontuações referentes às respostas assinaladas, realizando-se assim uma escala de avaliação
de dor articular com 5 níveis.
Foi possível verificar uma correlação estatisticamente significativa entre a idade e o PD
(P<0,05), em que os animais mais velhos tinham valores de PD mais elevados. Constatou-se
ainda que o PA e o PD tinham correlação estatisticamente significativa (P<0,01), ou seja, animais
com valores de PA mais elevados também tendiam a ter valores de PD mais elevados.
Através da comparação dos níveis de dor antes e depois do tratamento, foi possível
observar um decréscimo da dor dos gatos com a administração do INN-frunevetmab.
A administração do anticorpo monoclonal teve efeito positivo no maneio da dor articular
na DAD nos gatos estudados, com diferenças estatisticamente significativas no nível de dor
antes e após administração do INN-frunevetmab.
Joint pathologies, namely degenerative joint disease, are increasingly prevalent and recognized in clinical context, and treatment is as important as diagnosis. INN-frunevetmab, a monoclonal antibody that acts specifically on nerve growth factor, preventing it from binding to other receptors involved in the transmission of pain and inflammation signals emerged in feline medicine. The present study aimed to evaluate the response to the therapeutic use of INNfrunevetmab, in the treatment of chronic pain caused by degenerative joint disease in cats. This was performed at the Grupo Hospital do Gato in 50 cats diagnosed with degenerative joint disease. After the diagnosis, INN-frunevetmab was administered subcutaneously, once every 28 days at the recommended dose of 1-2.8 mg/kg. The level of pain in the animals was determined at two time points, before (PA) and three months after (PD) the administration of INNfrunevetmab, through a questionnaire with 12 questions. Each answer marked by the owner would correspond to 1 pain point. The data were collected and the scores of the answers were added up to produce a 5-level joint pain scale. It was possible to verify a statistically significant correlation between age and PD (P<0.05), in which the older animals had higher PD values. It was also found that PA and PD had statistically significant correlation (P<0.01), that is, animals with higher PA values also tended to have higher PD values. A decrease in the cats pain could be observed with the administration of INNfrunevetmab, when the pain levels before and after treatment were compared. The administration of the monoclonal antibody had a positive effect on the management of joint pain in DJD in the cats studied, with statistically significant differences in pain level before and after INN-frunevetmab administration.
Joint pathologies, namely degenerative joint disease, are increasingly prevalent and recognized in clinical context, and treatment is as important as diagnosis. INN-frunevetmab, a monoclonal antibody that acts specifically on nerve growth factor, preventing it from binding to other receptors involved in the transmission of pain and inflammation signals emerged in feline medicine. The present study aimed to evaluate the response to the therapeutic use of INNfrunevetmab, in the treatment of chronic pain caused by degenerative joint disease in cats. This was performed at the Grupo Hospital do Gato in 50 cats diagnosed with degenerative joint disease. After the diagnosis, INN-frunevetmab was administered subcutaneously, once every 28 days at the recommended dose of 1-2.8 mg/kg. The level of pain in the animals was determined at two time points, before (PA) and three months after (PD) the administration of INNfrunevetmab, through a questionnaire with 12 questions. Each answer marked by the owner would correspond to 1 pain point. The data were collected and the scores of the answers were added up to produce a 5-level joint pain scale. It was possible to verify a statistically significant correlation between age and PD (P<0.05), in which the older animals had higher PD values. It was also found that PA and PD had statistically significant correlation (P<0.01), that is, animals with higher PA values also tended to have higher PD values. A decrease in the cats pain could be observed with the administration of INNfrunevetmab, when the pain levels before and after treatment were compared. The administration of the monoclonal antibody had a positive effect on the management of joint pain in DJD in the cats studied, with statistically significant differences in pain level before and after INN-frunevetmab administration.
Description
Keywords
Doença articular degenerativa Dor Felinos INN-frunevetmab Questionários Degenerative joint disease INN-frunevetmab Feline Pain Questionnaires